{"title":"肥胖药物和精确营养:协同干预和综合方法在肥胖管理。","authors":"Alessandra Feraco, Elisabetta Camajani, Giovanna Muscogiuri, Luigi Barrea, Annamaria Colao, Massimiliano Caprio","doi":"10.1007/s13679-026-00695-7","DOIUrl":null,"url":null,"abstract":"<p><p>PURPOSE OF THE REVIEW: Obesity represents a major global health challenge associated with substantial metabolic, cardiovascular, and oncologic risk. Recent advances in anti-obesity pharmacotherapies, particularly GLP-1 receptor agonists and the dual GIP/GLP-1 agonist, have redefined clinical management by enabling unprecedented weight loss and significant cardiometabolic benefits. This review summarizes current evidence on how incretin-based therapies affect body composition, eating behavior, and long-term weight trajectories, with a focus on the need for nutritional strategies that support lean mass preservation and durable lifestyle changes. RECENT FINDINGS: Although incretin-based therapied effectively reduce body weight, the resulting weight loss includes a decline in fat-free mass, raising potential concerns about skeletal muscle preservation, particularly in vulnerable populations. Protein-enriched meal replacements (MRs) and structured dietary programs, including very low energy ketogenic therapy (VLEKT), have emerged as practical approaches to improve adherence, enhance fat loss, and stimulate muscle protein synthesis during medication-induced caloric restriction. Several studies indicate that MR-based interventions achieve greater weight loss and metabolic improvements than conventional diets, and that EAA-enriched formulations may provide additional advantages for preserving muscle mass. Combining MRs or VLEKT with incretin-based treatments may offer synergistic advantages by coupling pharmacological appetite regulation with controlled nutrient delivery and behavioral support. Structured nutritional interventions remain essential throughout pharmacotherapy and represent valuable alternatives when medications are discontinued or contraindicated. Overall, integrating incretin-based pharmacotherapy with optimized dietary strategies constitutes an approach to care that may enhance long-term effectiveness, promote nutritional rehabilitation, preserve muscle health, and address the needs of individuals at risk of sarcopenia. </p>","PeriodicalId":10846,"journal":{"name":"Current Obesity Reports","volume":"15 1","pages":""},"PeriodicalIF":17.0000,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Obesity medications and precision nutrition: synergistic interventions and integrated approach in obesity management.\",\"authors\":\"Alessandra Feraco, Elisabetta Camajani, Giovanna Muscogiuri, Luigi Barrea, Annamaria Colao, Massimiliano Caprio\",\"doi\":\"10.1007/s13679-026-00695-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>PURPOSE OF THE REVIEW: Obesity represents a major global health challenge associated with substantial metabolic, cardiovascular, and oncologic risk. Recent advances in anti-obesity pharmacotherapies, particularly GLP-1 receptor agonists and the dual GIP/GLP-1 agonist, have redefined clinical management by enabling unprecedented weight loss and significant cardiometabolic benefits. This review summarizes current evidence on how incretin-based therapies affect body composition, eating behavior, and long-term weight trajectories, with a focus on the need for nutritional strategies that support lean mass preservation and durable lifestyle changes. RECENT FINDINGS: Although incretin-based therapied effectively reduce body weight, the resulting weight loss includes a decline in fat-free mass, raising potential concerns about skeletal muscle preservation, particularly in vulnerable populations. Protein-enriched meal replacements (MRs) and structured dietary programs, including very low energy ketogenic therapy (VLEKT), have emerged as practical approaches to improve adherence, enhance fat loss, and stimulate muscle protein synthesis during medication-induced caloric restriction. Several studies indicate that MR-based interventions achieve greater weight loss and metabolic improvements than conventional diets, and that EAA-enriched formulations may provide additional advantages for preserving muscle mass. Combining MRs or VLEKT with incretin-based treatments may offer synergistic advantages by coupling pharmacological appetite regulation with controlled nutrient delivery and behavioral support. Structured nutritional interventions remain essential throughout pharmacotherapy and represent valuable alternatives when medications are discontinued or contraindicated. Overall, integrating incretin-based pharmacotherapy with optimized dietary strategies constitutes an approach to care that may enhance long-term effectiveness, promote nutritional rehabilitation, preserve muscle health, and address the needs of individuals at risk of sarcopenia. </p>\",\"PeriodicalId\":10846,\"journal\":{\"name\":\"Current Obesity Reports\",\"volume\":\"15 1\",\"pages\":\"\"},\"PeriodicalIF\":17.0000,\"publicationDate\":\"2026-02-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Obesity Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s13679-026-00695-7\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Obesity Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13679-026-00695-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Obesity medications and precision nutrition: synergistic interventions and integrated approach in obesity management.
PURPOSE OF THE REVIEW: Obesity represents a major global health challenge associated with substantial metabolic, cardiovascular, and oncologic risk. Recent advances in anti-obesity pharmacotherapies, particularly GLP-1 receptor agonists and the dual GIP/GLP-1 agonist, have redefined clinical management by enabling unprecedented weight loss and significant cardiometabolic benefits. This review summarizes current evidence on how incretin-based therapies affect body composition, eating behavior, and long-term weight trajectories, with a focus on the need for nutritional strategies that support lean mass preservation and durable lifestyle changes. RECENT FINDINGS: Although incretin-based therapied effectively reduce body weight, the resulting weight loss includes a decline in fat-free mass, raising potential concerns about skeletal muscle preservation, particularly in vulnerable populations. Protein-enriched meal replacements (MRs) and structured dietary programs, including very low energy ketogenic therapy (VLEKT), have emerged as practical approaches to improve adherence, enhance fat loss, and stimulate muscle protein synthesis during medication-induced caloric restriction. Several studies indicate that MR-based interventions achieve greater weight loss and metabolic improvements than conventional diets, and that EAA-enriched formulations may provide additional advantages for preserving muscle mass. Combining MRs or VLEKT with incretin-based treatments may offer synergistic advantages by coupling pharmacological appetite regulation with controlled nutrient delivery and behavioral support. Structured nutritional interventions remain essential throughout pharmacotherapy and represent valuable alternatives when medications are discontinued or contraindicated. Overall, integrating incretin-based pharmacotherapy with optimized dietary strategies constitutes an approach to care that may enhance long-term effectiveness, promote nutritional rehabilitation, preserve muscle health, and address the needs of individuals at risk of sarcopenia.
期刊介绍:
The main objective of Current Obesity Reports is to provide expert review articles on recent advancements in the interdisciplinary field of obesity research. Our aim is to offer clear, insightful, and balanced contributions that will benefit all individuals involved in the treatment and prevention of obesity, as well as related conditions such as cardiovascular diseases, endocrine disorders, gynecological issues, cancer, mental health, respiratory complications, and rheumatological diseases. We strive to redefine the way knowledge is expressed and provide organized content for the benefit of our readership.